Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported strong financial performance for FY26 ending March 2026. Standalone revenue grew marginally by 2% to INR 2,921.36 million, while consolidated revenue increased 6.9% to INR 3,325.99 million. However, profit after tax saw exceptional growth - standalone PAT surged 63.6% to INR 521 million and consolidated PAT nearly doubled by 99.4% to INR 574.84 million, driven by improved operational efficiency and segment performance. The Board declared a dividend of INR 11 per share (110%) for FY26. The company also completed divestment of its 43.81% stake in Texas Lifesciences Private Limited in March 2026. Statutory auditors issued an unmodified (clean) audit opinion on both standalone and consolidated financial statements.
The company delivered robust profitability growth with PAT nearly doubling on consolidated basis, which is positive for shareholders. Clean audit opinion and dividend declaration provide further confidence. The divestment of subsidiary may have one-time gains but reduces future consolidated revenue base.